Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Drug Class, Indication & Dosage Forms The global oncology drugs market will witness a robust CAGR of 11.53%, valued at $177.54 billion in 2021, expected to appreciate and reach $474.06 billion by 2030, confirms Strategic Market Research. Oncology studies the diagnosis, prevention, and treatment of cancer. The medicines that are used to aid in the treatment of cancer are referred to as oncology drugs. Oncology drugs are therapeutics used to treat and cure cancer caused by abnormal growth and division of abnormal cells. Oncology drugs inculcate different kinds of medications like targeted therapies, chemotherapy agents, hormone therapies, and immunotherapies. Globally, cancer is ranked among the leading causes of death. As asserted by WHO, in 2020, one out of every six deaths was from cancer. The World Cancer Research Fund implied that over 18 million cases were detected in 2020. Therefore, the market for cancer treatments, i.e., oncology drugs, is a tremendous opportunity for companies to invest resources. Key Industry Drivers - Factors Causing the Rapid Growth of The Market (Rising Number of Cancer Cases, Advancement in Treatment Types, Increased Use of Tobacco) There is an increase in the cases of cancers globally. According to studies, there has been a 4.5% yearly growth in the number of cancer cases since 2000. WHO estimates that over 400,000 children develop cancer each year. According to the American Cancer Society, approximately 89,000 deaths from cancer occurred in adolescents and young adults. As per the studies by the American Cancer Society, the mortality rate dropped by 32% between 1991 and 2019. Thus, it is an extremely beneficial and profitable field to invest in. The treatment options have increased drastically. The history of options for treatment starts with nitrogen mustard for treating lymph nodes (lymphoma), followed by radical surgery, which was a set of repeated surgeries to remove tumors and cancerous cells, and palliative pain management which was used to treat the pain associated with cancers. Since then, treatment methods have evolved to use chemotherapy, hormone therapy, immunotherapy, radiotherapy, biomarker testing, and stem cell therapy. According to Cancer Research UK, 27% of all cancer patients undergo radiotherapy, and 28% of the patients undergo chemotherapy. As per John Hopkins’ research, approximately 15-20% of patients achieve positive results with the use of Immunotherapy. Thus, with advancing treatment options for cancer being developed, we would see an uptick in demand for their availability to patients, thereby increasing the oncology drugs market size. Tobacco is among the primary causes of cancer globally. It causes lung, larynx, throat, kidney, colon and rectal, oesophagus, and mouth cancer. According to WHO, there are over 1.3 billion users of tobacco. Additionally, tobacco is responsible for over 8 million deaths yearly, of which tobacco use was the primary cause of the 1.8 million lung cancer deaths. Further, a WHO report states that the number of male tobacco users increased by 40 million between 2000 and 2018. Therefore, with the increased tobacco use, there would be a rapid surge in the various types of cancer. Hence, there would also be accelerated growth of the industry. Opportunities - Increased spending on R&D, Mergers, and Acquisition Pharmaceutical companies annually allocate a budget towards research and development, particularly in the field of oncology, and do this through oncology market research and drug development. As per a report published by the US Congressional Budget Office, pharmaceutical companies have, on average, increased their budget for R&D by 8.5% annually. In 2019, the money spent on R&D was USD 83 billion, which was ten times more than they spent in three previous decades. The report states that the emerging trend was increased spending on specialty drugs to treat rare conditions and cancers. Hence, we expect to see increased spending on R&D with a focus on oncology drugs. The pharmaceutical industry has relied on growing the market through various merger and acquisition deals. In June 2022, Bristol Myer Squibb announced that it would be acquiring Turning Point Therapeutics for USD 4.1 billion, primarily for their drugs elzovantinib and repotrectinib, both of which are cancer drugs. In April 2022, GlaxoSmithKline was in the process of acquiring Sierra Oncology for USD 1.9 billion with the aim to develop drugs that fight rare forms of cancer. In February 2022, Biocon Biologics agreed to acquire the biosimilars’ business from Vitaris, to further develop their portfolio of cancer and diabetes drugs. Therefore, in the short-term and long-term period, we would continue to see such deals between pharmaceutical companies, enhancing the market for cancer drugs. Restraints The major restrictions in entering and having a long-term continued development in the market are the high capital costs involved in R&D and the time the drugs take for their approval. Market Analysis Of Different Segments Covered in the Report Based on Therapy Chemotherapy Immunotherapy Targeted Therapy Hormonal Therapy Based on Class of Drugs Cytotoxic Drugs Alkylating Agents Antimetabolites Targeted Drugs Monoclonal Antibodies Hormonal Drugs Others Based on Indication Breast Cancer Lung Cancer Colon and Rectal Cancer Prostate Cancer Skin Cancer Stomach Cancer Others Based on Dosage Solid Capsules Tablets Liquid Injectable Based on Distribution Channel Retail Pharmacies Hospital Pharmacies Online Pharmacies Others Regional Coverage Analysis North America Canada USA Mexico Rest of North America Asia Pacific China India Indonesia Taiwan Thailand South Korea Japan Australia - New Zealand Rest of Asia Pacific Europe Germany France United Kingdom Italy Spain Russia Netherlands Turkey Rest of Europe Latin America, Middle East, and Africa (LAMEA) Argentina Brazil Colombia Chile Peru Saudi Arabia Oman Qatar UAE Morocco Egypt Nigeria Algeria South Africa Rest of LAMEA Therapy Analysis & Insights The targeted therapy dominated the market share with 52%. The reason for this is the effectiveness of targeted therapies against cancer. According to studies, the effectiveness increased by over 50% between 2007 and 2020. As per an American Cancer Society (ACS) study, the survival rate of lung cancer increased from 21 per 100 in 2004 to 31 per 100 by 2018. The study associates the link between increased use of targeted therapies and shows the increased survival rate among cancer patients. Therefore, the increased use of targeted therapies has further bolstered the market. Drug Class Analysis & Insights The targeted drugs held the dominant share in the market. Targeted drugs are usually monoclonal antibodies, or they can be small-molecule drugs. Small molecule drugs are small enough to enter cancer cells and are used as targeted drugs. Monoclonal antibodies are proteins that attach to cancer cells and act as markers to the body’s immune system to target the cells. Alternatively, they can prevent the cells from growing and can cause them to self-destruct. Alemtuzumab is a monoclonal antibody drug that is used to treat relapsing-remitting multiple sclerosis (RRMS). According to European Medical Agency, controlled studies have shown a reduction in the relapse rate - 57% in two years. In the same study, the relapse rates were 67% and 77%, with 12mg/day and 24mg/day, respectively. Therefore, with the increased effectiveness of targeted drugs in cancers and other diseases, we would see an overwhelming rise in the use of monoclonal antibodies. Indication Analysis & Insights The breast cancer holds the highest oncology drugs market share because of its high occurrence and detection rates. According to the data from WHO, over 2.3 million cases of breast cancer were detected in 2020, and over 685,000 deaths. Cancer Research UK identifies breast cancer as the most common type of cancer in the island nation. A total of over 404,000 cases of breast cancer were detected in EU-28 countries. Some commonly used breast cancer drugs and breast cancer therapeutics are Abemaciclib, Cyclophosphamide, Megestrol Acetate, Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf), and Zoladex (Goserelin Acetate). Further, the commonly used metastatic breast cancer treatments are Capecitabine, Carboplatin, and Cisplatin. The high rates of cancer are associated with high levels of estrogen, which are a consequence of increasing stress and obesity levels. According to the statistics from the CDC, 41.9% of the American population is obese. Between 1999 and 2017, the levels of obesity in the country increased from 30.5% to 41.9%. As per studies from the American Psychological Association, over 67% of adults in the study experienced higher levels of stress in 2020 due to the pandemic. Thus, with higher stress and obesity levels among the population, we would see and witness a rapid surge in breast cancer cases. Dosage Analysis & Insights The injectables held the highest market share. Injectables are preferred because the drugs bypass the first-pass metabolism and the factor of gastric action on the drugs is negligible. Additionally, the drug acts faster when injected rather than ingested. As per the ACS, most chemotherapy drugs are injected into the body through different methods such as intravenously, intramuscular, intrathecal, or intra-arterial. Further, in the ACS report on survival rates using, chemotherapy is used for an array of cancers such as breast, kidney, and lung, among others, and has seen high stage-zero, five-year survival rates - breast cancer,90%; bladder cancer,95%; lung cancer, 29%; prostate cancer,99%. Thus, the market will see a sharp rise with phenomenal statistics for injectable chemotherapy. Distribution Channels Analysis & Insights The hospital pharmacies dominate the segment. This is associated with the need for the drugs at hospitals and clinics and ease of access for physicians and patients to get the right type of drug at hospitals themselves. According to the CDC, over 860.4 million visits were made to physician’s offices, including hospitals, individual clinics, and treatment facilities. The COVID-19 global pandemic caused a surge in visits. Therefore, with more people visiting hospitals, we would see an increase in the prescriptions delivered and consequently a rise in sales of cancer drugs. Regional Analysis & Insights North America dominated the market for oncology drugs because of the high prevalence of cancers in the region, the presence of multiple pharmaceutical companies, and overall advanced healthcare infrastructure. According to CDC statistics related to cancer, the cancer incidence rate was 439 new cases and 146 deaths per 100,000 people. As per Health Canada, approximately 2 in 5 Canadians would be diagnosed with at least one form of cancer in their lifetime. As per research, Mexico had approximately 86 cases of cancer per 100,000 population. There are more than 6,000 hospital and patient care institutions in the US and over 1200 hospitals in Canada, among the highest numbers in the world. Therefore, with high cancer occurrence rates and advanced healthcare infrastructure, North America will continue to dominate the regional segment for the foreseeable future. Global Oncology Drugs Market Competitive Landscape Analysis The major biotechnological and pharmaceutical companies involved in the field of cancer drug development are: AbbVie AMGEN, Inc. Astellas Pharma Inc. AstraZeneca plc Bayer AG BeiGene Bristol Myers Squibb Celgene Corporation Daiichi Sankyo Co. Ltd Dr Reddy’s Laboratories Gilead Science, Inc. GSK plc Incyte Johnson & Johnson Eli Lilly and Co Merck & Co., In Novartis International AG Pfizer Inc. Roche Holding AG Sanofi SA. Takeda Pharmaceutical Company, Ltd. Oncology Drugs Market Report Coverage Report Attribute Details Period of Forecast 2021 - 2030 The market size value in 2021 USD 177.54 billion The revenue forecast in 2030 USD 474.06 billion Growth rate CAGR of 11.53 % The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Therapy, Drug Class, Indication, Dosage, Distribution Channel, and Region. By Therapy Chemotherapy, Hormonal, Radiotherapy, and Targeted. By Drug Class Cytotoxic, Hormonal, Targeted, and Others By Indication Colon, Rectal, Lung, Breast, Prostate, and Others By Dosage Liquid, Injectable and Solid By Distribution Channel Hospital, Retail, Online, and Others By Region North America, Europe, Asia-Pacific, and LAMEA Country Scope China, Canada, USA, India, Denmark, Ireland, France, The Netherlands, Hungary, Belgium, Slovenia, and Norway. Company Usability Profiles AbbVie, Takeda Pharmaceutical Company, Ltd., Sanofi S.A., Roche Holding AG, Pfizer Inc., Novartis International AG, Merck & Co., Johnson & Johnson, Incyte, GSK plc, Gilead Science, Inc., Eli Lilly, and Co, Dr. Reddy’s Laboratories, Daiichi Sankyo Co. Ltd, Celgene Corporation, Bristol Myers Squibb, BeiGene, Bayer AG, AstraZeneca plc, Astellas Pharma Inc., and AMGEN, Inc. Products Manufactured by Leading Market Players are: Name Feature Key Player Herceptin (trastuzumab) HER2- targeted therapy, blocking of receptors. Roche Imbruvica (ibrutinib) Treats the following - graft v host disease, chronic lymphocytic leukemia, marginal zone lymphoma. Janssen (Johnson & Johnson) Sarclisa (isatuximab-irfc) Prevents remission of multiple myeloma. Sanofi FASLODEX (fulvestrant) Treatment of metastatic breast cancer. AstraZeneca Recent Developments In July 2022, the UK’s National Health Service (NHS) began a trial to deliver chemotherapy drugs to the UK territory of Isle of Wight. The program's objective is to decrease the time taken to deliver the drugs from four hours to thirty minutes. The secondary objective is to reduce the carbon emissions in the process by over 50%. In July 2022, Eli Lilly got a recommendation for their drug Verzenios from the National Institute for Health and Care Excellence, UK. The drug treatment plan, combined with endocrine therapy, was recommended to treat hormone receptor-positive, node-positive and HER2-negative breast cancer patients with a higher recurrence rate. In June 2022, the European Society for Medical Oncology (ESMO) began registrations for their conference to be held in August. The primary aim of the ESMO Congress,2022, is to discuss and deliberate on the new findings and treatment options for European oncology drugs. In June 2022, Schrödinger, a molecular modeling company, received approval from the FDA to run a trial to study the molecular compounds that can help treat non-Hodgkin’s lymphoma. The ML platform helps the company identify 78 compounds from over 8 billion that can be synthesized to create viable treatment compounds. In June 2022, Novartis AG announced to open its new manufacturing facility in Mumbai, India. The plant is set to manufacture generic oral chemotherapy drugs for the global market. In June 2022, the Sheba Medical Center collaborated with Enlivex Therapeutics to enter into phase I/II clinical trials to test a new drug, Allocetra. The drug is to be used alongside chemotherapy and would help in the treatment plan for peritoneal cancer. In June 2022, the FDA approved on a contingent basis the oral medication zanubrutinib to treat marginal zone lymphoma. This type and kind of cancer is prevalent among children, adolescents, and young adults. The study found that using zanubrutinib, the cancers shrank by 80% and went into remission in 20% of the patients, thus adding the medicine to treat the specific lymphoma. In June 2022, the combination of Mekinist and Tafinlar medicines were approved by FDA for the treatment of advanced solid tumors. The combination is currently used to treat melanoma, thyroid, and lung cancers. The combination is approved for treating tumors with the BRAF 600E gene mutation. Frequently Asked Question About This Report How big is the oncology drugs market? The global oncology drugs market size was $ 177.54 Bn in 2021 and is predicted to reach $ 474.06 Bn by 2030, with a CAGR of 11.53 %. Which segment would lead by drug class? In the drug class, targeted therapy drugs led the market. What are the oncology drugs market growth? The global oncology drugs market is expected to grow at a compound annual growth rate (CAGR) of 11.53 % from 2021 to 2030 to reach USD 474.06 Billion by 2030. Which are the major firms involved in this market? The major players in the oncology drugs market are Johnson&Johnson, Incyte, GSK plc, Gilead Science, Inc., Eli Lilly and Co, Dr Reddy’s Laboratories, Daiichi Sankyo Co. Ltd, Celgene Corporation, Bristol Myers Squibb, BeiGene, AbbVie, Takeda Pharmaceutical Company, Ltd., Sanofi S.A., Roche Holding AG, Pfizer Inc., Novartis International AG, Merck & Co., Bayer AG, AstraZeneca plc, Astellas Pharma Inc., and AMGEN, Inc. What was the value of the North American market in 2020? As of 2020, the North American market was worth USD 73.19 billion, with the US oncology drugs market size being USD 58.32 billion. Sources https://www.who.int/news-room/fact-sheets/detail/tobacco https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473764/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438392/ https://www.cdc.gov/obesity/data/adult.html https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21654 https://www.cancer.org/cancer/cancer-in-adolescents/key-statistics.html https://www.cancerresearchuk.org/health-professional/cancer-statistics/treatment 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Oncology Drugs Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Oncology Drugs Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Indication Business Analysis 4.4.1 market, By Indication, 2021 - 2030 (USD Million) 4.5 By Distribution Channel Business Analysis 4.5.1 market, By Distribution Channel, 2021 - 2030 (USD Million) 4.6 Dosage Business Analysis 4.6.1 market, By Dosage, 2021 - 2030 (USD Million) 4.7 Class of Drugs Business Analysis 4.7.1 market, By Class of Drugs, 2021 - 2030 (USD Million) 4.8 Therapy Analysis 4.8.1 market, By Therapy, 2021 - 2030 (USD Million) 4.9 Value Chain Analysis 4.10 Market Variable Analysis 4.10.1 Market Drivers Analysis 4.10.2 Market Restraints Analysis 4.11 Business Environment Analysis Tool 4.11.1 market PEST analysis 4.11.2 market Porter’s analysis 4.12 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Class of Drugs Analysis 5.11.1. Trends in Class of Drugs (2014-2021) 5.11.2. Trends in Class of Drugs (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Indication 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Indication Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Breast Cancer 7.3.1. Breast Cancer market, 2021 - 2030 (USD Million) 7.4. Lung Cancer 7.4.1. Lung Cancer market, 2021 - 2030 (USD Million) 7.5. Colon and Rectal Cancer 7.5.1. Colon and Rectal Cancer market, 2021 - 2030 (USD Million) 7.6. Prostate Cancer 7.6.1. Prostate Cancer market, 2021 - 2030 (USD Million) 7.7. Skin Cancer 7.7.1. Skin Cancer market, 2021 - 2030 (USD Million) 7.8. Stomach Cancer 7.8.1. Stomach Cancer market, 2021 - 2030 (USD Million) 7.9. Others 7.9.1. Others market, 2021 - 2030 (USD Million) 8. Market: By Distribution Channel Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Retail Pharmacies 8.3.1. Retail Pharmacies market, 2021 - 2030 (USD Million) 8.4. Hospital Pharmacies 8.4.1. Hospital Pharmacies market, 2021 - 2030 (USD Million) 8.5. Online Pharmacies 8.5.1. Online Pharmacies market, 2021 - 2030 (USD Million) 8.6. Others 8.6.1. Others market, 2021 - 2030 (USD Million) 9. Market: By Dosage Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Solid 9.3.1. Solid market, 2021 - 2030 (USD Million) 9.3.1.1 Capsules market, 2021 - 2030 (USD Million) 9.3.1.2 Tablets market, 2021 - 2030 (USD Million) 9.4. Liquid 9.4.1. Liquid market, 2021 - 2030 (USD Million) 9.5. Injectable 9.5.1. Injectable market, 2021 - 2030 (USD Million) 10. Market: By Class of Drugs Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Cytotoxic Drugs 10.3.1. Cytotoxic Drugs market, 2021 - 2030 (USD Million) 10.3.1. Alkylating Agents market, 2021 - 2030 (USD Million) 10.3.1. Antimetabolites market, 2021 - 2030 (USD Million) 10.4. Targeted Drugs 10.4.1. Targeted Drugs market, 2021 - 2030 (USD Million) 10.5. Monoclonal Antibodies 10.5.1. Monoclonal Antibodies market, 2021 - 2030 (USD Million) 10.6. Hormonal Drugs 10.6.1. Hormonal Drugs market, 2021 - 2030 (USD Million) 10.7. Others 10.7.1. Others market, 2021 - 2030 (USD Million) 11. Market: By Therapy Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Chemotherapy 11.3.1. Chemotherapy market, 2021 - 2030 (USD Million) 11.4. Immunotherapy 11.4.1. Immunotherapy market, 2021 - 2030 (USD Million) 11.5. Targeted Therapy 11.5.1. Targeted Therapy market, 2021 - 2030 (USD Million) 11.6. Hormonal Therapy 11.6.1. Hormonal Therapy market, 2021 - 2030 (USD Million) 12. Market: Regional Outlook 12.1 North America 12.1.1. North America market, By Indication, 2021 - 2030 (USD Million) 12.1.2. North America market, By Distribution Channel, 2021 - 2030 (USD Million) 12.1.3. North America market, by Class of Drugs, 2021 - 2030 (USD Million) 12.1.4. North America market, by Therapy, 2021 - 2030 (USD Million) 12.1.5. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Indication, 2021 - 2030 (USD Million) 12.1.4.1.2. U.S. market, By Distribution Channel, 2021 - 2030 (USD Million) 12.1.4.1.3. U.S. market, by Class of Drugs, 2021 - 2030 (USD Million) 12.1.4.1.4. U.S. market, by Therapy, 2021 - 2030 (USD Million) 12.1.4.1.5. U.S. market, by Country, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Indication, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Distribution Channel, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by Class of Drugs, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Indication, 2021 - 2030 (USD Million) 12.2.2. Europe market, By Distribution Channel, 2021 - 2030 (USD Million) 12.2.3. Europe market, by Class of Drugs, 2021 - 2030 (USD Million) 12.2.4. Europe market, by Therapy, 2021 - 2030 (USD Million) 12.2.5. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Indication, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Distribution Channel, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by Class of Drugs, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Indication, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Distribution Channel, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by Class of Drugs, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Indication, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Distribution Channel, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by Class of Drugs, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Indication, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Distribution Channel, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by Class of Drugs, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Indication, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Distribution Channel, 2021 - 2030 (USD Million) 12.3.3. Asia Pacific market, by Class of Drugs, 2021 - 2030 (USD Million) 12.3.4. Asia Pacific market, by Therapy, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Indication, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Distribution Channel, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by Class of Drugs, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Indication, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Distribution Channel, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by Class of Drugs, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Indication, 2021 - 2030 (USD Million) 12.3.4.3.2. Japan market, By Distribution Channel, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by Class of Drugs, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Indication, 2021 - 2030 (USD Million) 12.3.4.4.2. South Korea market, By Distribution Channel, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by Class of Drugs, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Indication, 2021 - 2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Distribution Channel, 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by Class of Drugs, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Indication, 2021 - 2030 (USD Million) 12.4.2. Latin America market, By Distribution Channel, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by Class of Drugs, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by Therapy, 2021 - 2030 (USD Million) 12.4.5. Latin America market, by Dosage, 2021 - 2030 (USD Million) 12.4.6. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Indication, 2021 - 2030 (USD Million) 12.4.4.1.2. Brazil market, By Distribution Channel, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by Class of Drugs, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Indication, 2021 - 2030 (USD Million) 12.4.4.2.2. Mexico market, By Distribution Channel, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by Class of Drugs, 2021 - 2030 (USD Million) 12.4.4.3. Rest of Latin America 12.4.4.3.1. Rest of the Latin America market, By Indication, 2021 - 2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Distribution Channel, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by Class of Drugs, 2021 - 2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Indication, 2021 - 2030 (USD Million) 12.5.2. MEA market, By Distribution Channel, 2021 - 2030 (USD Million) 12.5.3. MEA market, by Class of Drugs, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Dosage, 2021 - 2030 (USD Million) 12.5.5. MEA market, by Therapy, 2021 - 2030 (USD Million) 12.5.6. MEA market, by region, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 AbbVie 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Indication Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. AMGEN, Inc 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Indication Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. Astellas Pharma Inc 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Indication Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. AstraZeneca plc 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Indication Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Bayer AG 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Indication Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. BeiGene 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Indication Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Bristol Myers Squibb 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Indication Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Celgene Corporation 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Indication Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. Daiichi Sankyo Co. Ltd 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Indication Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. Dr Reddy’s Laboratories 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Indication Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. Gilead Science, Inc 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Indication Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. GSK plc 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Indication Portfolio Analysis 13.12.4. Business Strategy & Recent Development 13.13. Incyte 13.13.1. Company overview 13.13.2. Financial performance 13.13.3. Indication Portfolio Analysis 13.13.4. Business Strategy & Recent Development 13.14. Johnson & Johnson 13.14.1. Company overview 13.14.2. Financial performance 13.14.3. Indication Portfolio Analysis 13.14.4. Business Strategy & Recent Development 13.15. Eli Lilly and Co 13.15.1. Company overview 13.15.2. Financial performance 13.15.3. Indication Portfolio Analysis 13.15.4. Business Strategy & Recent Development 13.16. Merck & Co., In 13.16.1. Company overview 13.16.2. Financial performance 13.16.3. Indication Portfolio Analysis 13.16.4. Business Strategy & Recent Development 13.17. Novartis International AG 13.17.1. Company overview 13.17.2. Financial performance 13.17.3. Indication Portfolio Analysis 13.17.4. Business Strategy & Recent Development 13.18. Pfizer Inc 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Indication Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.19. Roche Holding AG 13.19.1. Company overview 13.19.2. Financial performance 13.19.3. Indication Portfolio Analysis 13.19.4. Business Strategy & Recent Development 13.20. Sanofi SA 13.20.1. Company overview 13.20.2. Financial performance 13.20.3. Indication Portfolio Analysis 13.20.4. Business Strategy & Recent Development 13.21. Takeda Pharmaceutical Company, Ltd 13.21.1. Company overview 13.21.2. Financial performance 13.21.3. Indication Portfolio Analysis 13.21.4. Business Strategy & Recent Development List of Tables (95 Tables) TABLE 1. MARKET, By Indication, 2021-2030 (USD Million) TABLE 2. Breast Cancer, BY REGION, 2021-2030 (USD Million) TABLE 3. Lung Cancer, BY REGION, 2021-2030 (USD Million) TABLE 4. Colon and Rectal Cancer, BY REGION, 2021-2030 (USD Million) TABLE 5. Prostate Cancer, BY REGION, 2021-2030 (USD Million) TABLE 6. Skin Cancer, BY REGION, 2021-2030 (USD Million) TABLE 7. Stomach Cancer, BY REGION, 2021-2030 (USD Million) TABLE 8. Others, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET, By Distribution Channel, 2021-2030 (USD Million) TABLE 10. Retail Pharmacies, BY REGION, 2021-2030 (USD Million) TABLE 11. Hospital Pharmacies, BY REGION, 2021-2030 (USD Million) TABLE 12. Online Pharmacies, BY REGION, 2021-2030 (USD Million) TABLE 13. Others, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET, BY CLASS OF DRUGS, 2021-2030 (USD Million) TABLE 15. Cytotoxic Drugs, BY REGION, 2021-2030 (USD Million) TABLE 16. Alkylating Agents, BY REGION, 2021-2030 (USD Million) TABLE 17. Antimetabolites, BY REGION, 2021-2030 (USD Million) TABLE 18. Targeted Drugs, BY REGION, 2021-2030 (USD Million) TABLE 19. Monoclonal Antibodies, BY REGION, 2021-2030 (USD Million) TABLE 20. Hormonal Drugs, BY REGION, 2021-2030 (USD Million) TABLE 21. Others, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET, By Dosage, 2021-2030 (USD Million) TABLE 23. Solid, BY REGION, 2021-2030 (USD Million) TABLE 24. Capsules, BY REGION, 2021-2030 (USD Million) TABLE 25. Tablets, BY REGION, 2021-2030 (USD Million) TABLE 26. Liquid, BY REGION, 2021-2030 (USD Million) TABLE 27. Injectable, BY REGION, 2021-2030 (USD Million) TABLE 28. MARKET, By Therapy, 2021-2030 (USD Million) TABLE 29. Chemotherapy, BY REGION, 2021-2030 (USD Million) TABLE 30. Immunotherapy, BY REGION, 2021-2030 (USD Million) TABLE 31. Targeted Therapy, BY REGION, 2021-2030 (USD Million) TABLE 32. Hormonal Therapy, BY REGION, 2021-2030 (USD Million) TABLE 33. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 34. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 35. NORTH AMERICA MARKET, By Indication, 2021-2030 (USD Million) TABLE 36. NORTH AMERICA MARKET, By Distribution Channel, 2021-2030 (USD Million) TABLE 37. NORTH AMERICA MARKET, BY CLASS OF DRUGS, 2021-2030 (USD Million) TABLE38. NORTH AMERICA MARKET, BY Therapy, 2021-2030 (USD Million) TABLE 39. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 40. EUROPE MARKET, By Indication, 2021-2030 (USD Million) TABLE 41. EUROPE MARKET, By Distribution Channel, 2021-2030 (USD Million) TABLE 42. EUROPE MARKET, BY CLASS OF DRUGS, 2021-2030 (USD Million) TABLE 43. EUROPE MARKET, BY Therapy, 2021-2030 (USD Million) TABLE 44. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 45. ASIA-PACIFIC MARKET, By Indication, 2021-2030 (USD Million) TABLE 46. ASIA-PACIFIC MARKET, By Distribution Channel, 2021-2030 (USD Million) TABLE 47. ASIA-PACIFIC MARKET, BY CLASS OF DRUGS, 2021-2030 (USD Million) TABLE 48. ASIA-PACIFIC MARKET, BY Therapy, 2021-2030 (USD Million) TABLE 49. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 50. LAMEA MARKET, By Indication, 2021-2030 (USD Million) TABLE 51. LAMEA MARKET, By Dosage, 2021-2030 (USD Million) TABLE 52. LAMEA MARKET, BY CLASS OF DRUGS, 2021-2030 (USD Million) TABLE 53. LAMEA MARKET, BY Therapy, 2021-2030 (USD Million) TABLE 54. AbbVie: COMPANY SNAPSHOT TABLE 55. AbbVie: OPERATING SEGMENTS TABLE 56. AMGEN, Inc: COMPANY SNAPSHOT TABLE 57. AMGEN, Inc: OPERATING SEGMENTS TABLE 58. Astellas Pharma Inc: COMPANY SNAPSHOT TABLE 59. Astellas Pharma Inc: OPERATING SEGMENTS TABLE 60. AstraZeneca plc: COMPANY SNAPSHOT TABLE 61. AstraZeneca plc: OPERATING SEGMENTS TABLE 62. Bayer AG: COMPANY SNAPSHOT TABLE 63. Bayer AG: OPERATING SEGMENTS TABLE 64. BeiGene: COMPANY SNAPSHOT TABLE 65. BeiGene: OPERATING SEGMENTS TABLE 66. Bristol Myers Squibb: COMPANY SNAPSHOT TABLE 67. Bristol Myers Squibb: OPERATING SEGMENTS TABLE 68. Celgene Corporation: COMPANY SNAPSHOT TABLE 69. Celgene Corporation: OPERATING SEGMENTS TABLE 70. Daiichi Sankyo Co. Ltd: COMPANY SNAPSHOT TABLE 71. Daiichi Sankyo Co. Ltd: OPERATING SEGMENTS TABLE 72. Dr Reddy’s Laboratories: COMPANY SNAPSHOT TABLE 73. Dr Reddy’s Laboratories: OPERATING SEGMENTS TABLE 74. Gilead Science, Inc: COMPANY SNAPSHOT TABLE 75. Gilead Science, Inc: OPERATING SEGMENTS TABLE 76. GSK plc: COMPANY SNAPSHOT TABLE 77. GSK plc: OPERATING SEGMENTS TABLE 78. Incyte: COMPANY SNAPSHOT TABLE 79. Incyte: OPERATING SEGMENTS TABLE 80. Johnson & Johnson: COMPANY SNAPSHOT TABLE 81. Johnson & Johnson: OPERATING SEGMENTS TABLE 82. Eli Lilly and Co: COMPANY SNAPSHOT TABLE 83. Eli Lilly and Co: OPERATING SEGMENTS TABLE 84. Merck & Co., In: COMPANY SNAPSHOT TABLE 85. Merck & Co., In: OPERATING SEGMENTS TABLE 86. Novartis International AG: COMPANY SNAPSHOT TABLE 87. Novartis International AG: OPERATING SEGMENTS TABLE 88. Pfizer Inc: COMPANY SNAPSHOT TABLE 89. Pfizer Inc: OPERATING SEGMENTS TABLE 90. Roche Holding AG: COMPANY SNAPSHOT TABLE 91. Roche Holding AG: OPERATING SEGMENTS TABLE 92. Sanofi SA: COMPANY SNAPSHOT TABLE 93. Sanofi SA: OPERATING SEGMENTS TABLE 94. Takeda Pharmaceutical Company, Ltd: COMPANY SNAPSHOT TABLE 95. Takeda Pharmaceutical Company, Ltd: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Indication-Based Estimation Figure 6 Top 21 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Oncology Drugs Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Oncology Drugs Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Distribution Channel, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Class of Drugs, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Indication, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Therapy, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Dosage, 2019 vs. 2025 (USD Million) Figure 16 Geographical Snapshot of the Market Figure 17 Breast Cancer to Witness Higher CAGR in Indication Segment during Forecast Period. Figure 18 Targeted Drugs to Witness Higher CAGR in Class of Drugs Segment during Forecast Period. Figure 19 Injectable to Witness Higher CAGR in Dosage Segment during Forecast Period. Figure 20 Targeted Therapy to Witness Higher CAGR in Therapy Segment during Forecast Period. Figure 21 Hospital Pharmacies to Witness Higher CAGR in the Distribution Channel Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview